ASP Isotopes Inc. has announced a significant supply agreement with Isotopia Molecular Imaging Ltd. to provide enriched Gadolinium-160 (Gd-160), a crucial precursor for producing Terbium-161 (Tb-161). The four-year contract, starting in 2026, is valued at a minimum of $1 million annually. This partnership aims to address longstanding supply challenges for Gd-160, facilitating the advancement of Tb-161-based therapies for cancers such as prostate cancer and neuroendocrine tumors. ASP Isotopes will utilize its Quantum Enrichment technology to ensure a stable supply of Gd-160, supporting Isotopia's efforts to scale production and advance Tb-161-labeled drug candidates toward commercialization. This collaboration is expected to accelerate the clinical adoption of Tb-161, potentially redefining cancer treatment paradigms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.